NEW YORK, NY / ACCESSWIRE / April 15, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CRNC Shareholders Click Here: https://www.zlk.com/pslra-1/cerence-inc-loss-submission-form?prid=26045&wire=1
AKBA Shareholders Click Here: https://www.zlk.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?prid=26045&wire=1
ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=26045&wire=1
* ADDITIONAL INFORMATION BELOW *
Cerence Inc. (NASDAQ:CRNC)
CRNC Lawsuit on behalf of: investors who purchased February 8, 2021 – February 4, 2022
Lead Plaintiff Deadline : April 26, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cerence-inc-loss-submission-form?prid=26045&wire=1
According to the filed complaint, during the class period, Cerence Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence’s software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company’s software licenses by pulling forward sales; and (3) as a result of the above, defendants’ statements about Cerence’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
Akebia Therapeutics, Inc. (NASDAQ:AKBA)
AKBA Lawsuit on behalf of: investors who purchased June 28, 2018 – September 2, 2020
Lead Plaintiff Deadline : May 13, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?prid=26045&wire=1
According to the filed complaint, during the class period, Akebia Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
AbbVie Inc. (NYSE:ABBV)
ABBV Lawsuit on behalf of: investors who purchased April 30, 2021 – August 31, 2021
Lead Plaintiff Deadline : June 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=26045&wire=1
According to the filed complaint, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/697688/CLASS-ACTION-UPDATE-for-CRNC-AKBA-and-ABBV-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
